Pharmasset, Inc.

303-A College Road East,
Princeton, New Jersey 08540
United States,
(609)613-4100
www.pharmasset.com

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset’s research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.

Pharmasset was acquired by Gilead Sciences on November 21, 2011.

Join Mergr to view all 163 acquisitions of life science companies in 2011, including 18 acquisitions by private equity firms, and 145 by strategics.

Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2011. The largest life science acquisition in 2011 was Genzyme - which was acquired by Sanofi SA for $20.1B.

Join Mergr to view this profile - and discover more life science acquisitions of companies like Pharmasset.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 113K M&A Transactions
  • 123K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.